Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie om bijwerkingen, verandering in ziekteactiviteit en hoe intraveneus en subcutaan Risankizumab door het lichaam van pediatrische deelnemers met matig tot ernstig actieve ziekte van Crohn beweegt te beoordelen (RISE)

15 oktober 2026 bijgewerkt door: AbbVie

Een multicenter fase 3-onderzoek ter evaluatie van de farmacokinetiek, werkzaamheid en veiligheid van risankizumab met open-label inductie, gerandomiseerde dubbelblinde onderhoudsbehandeling en langdurige verlengingsperioden bij pediatrische proefpersonen (leeftijd 2 tot < 18 jaar) met Matig tot ernstig actieve ziekte van Crohn

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.

Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.

Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Studie Overzicht

Toestand

Werving

Conditie

Studietype

Ingrijpend

Inschrijving (Geschat)

110

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Brussels, België, 1020
        • Werving
        • Hospital Universite Enfants Reine Fabiola /ID# 255112
      • Liège, België, 4000
        • Werving
        • Groupe Sante CHC - Clinique du MontLegia /ID# 255620
    • Antwerpen
      • Edegem, Antwerpen, België, 2650
        • Werving
        • Uza /Id# 255114
    • Brussels Capital
      • Brussels, Brussels Capital, België, 1200
        • Werving
        • Cliniques Universitaires UCL Saint-Luc /ID# 255108
      • Jette, Brussels Capital, België, 1090
        • Werving
        • Universitair Ziekenhuis Brussel /ID# 255109
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, België, 3000
        • Werving
        • Universitair Ziekenhuis Leuven /ID# 255098
      • Plovdiv, Bulgarije, 4002
        • Werving
        • UMHAT Sveti Georgi EAD /ID# 255386
      • Sofia, Bulgarije, 1606
        • Voltooid
        • Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
      • Varna, Bulgarije, 9009
        • Werving
        • UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
    • Alberta
      • Calgary, Alberta, Canada, T3B 6A8
        • Werving
        • Alberta Children's Hospital /ID# 255357
      • Edmonton, Alberta, Canada, T6G 1C9
        • Werving
        • Edmonton Clinic Health Academy /ID# 255361
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • Werving
        • BC Children's Hospital /ID# 255359
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Werving
        • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100045
        • Werving
        • Beijing Children's Hospital /ID# 256081
      • Beijing, Beijing Municipality, China, 100191
        • Werving
        • Peking University Third Hospital /ID# 255876
        • Contact:
          • Site Coordinator
          • Telefoonnummer: +86 010-82266699
    • Guangdong
      • Guangzhou, Guangdong, China, 510620
        • Werving
        • Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
      • Guangzhou, Guangdong, China, 510655
        • Werving
        • The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
    • Henan
      • Zhengzhou, Henan, China, 450018
        • Werving
        • Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
    • Hunan
      • Changsha, Hunan, China, 410007
        • Werving
        • Hunan Children's Hospital /ID# 255610
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Werving
        • Jiangxi Provincial Children's Hospital /ID# 255564
    • Liaoning
      • Shenyang, Liaoning, China, 110022
        • Werving
        • Shengjing Hospital of China Medical University /ID# 255563
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200062
        • Werving
        • Children's Hospital of Shanghai /ID# 255531
      • Shanghai, Shanghai Municipality, China, 200065
        • Werving
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
    • Bavaria
      • Munich, Bavaria, Duitsland, 80337
        • Werving
        • Dr. von Haunerschen Kinderspital /ID# 255577
    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, Duitsland, 48149
        • Werving
        • Universitaetsklinikum Muenster /ID# 256762
      • Paris, Frankrijk, 75015
        • Werving
        • AP-HP - Hopital Necker /ID# 255608
    • Centre-Val de Loire
      • Tours, Centre-Val de Loire, Frankrijk, 37044
        • Werving
        • CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
    • New Aquitaine
      • Bordeaux, New Aquitaine, Frankrijk, 33076
        • Werving
        • Chu Bordeaux - Hopital Pellegrin /ID# 257060
    • Occitanie
      • Toulouse, Occitanie, Frankrijk, 31059
        • Werving
        • CHU Toulouse - Hopital Paule de Viguier /ID# 255609
    • Rhone
      • Bron, Rhone, Frankrijk, 69500
        • Werving
        • Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
    • Central District
      • Petah Tikva, Central District, Israël, 4920235
        • Werving
        • Schneider Children's Medical Center /ID# 254950
    • Jerusalem
      • Jerusalem, Jerusalem, Israël, 91031
        • Werving
        • Shaare Zedek Medical Center /ID# 254951
      • Messina, Italië, 98125
        • Werving
        • Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
    • Genova
      • Genoa, Genova, Italië, 16147
        • Werving
        • IRCCS Istituto Giannina Gaslini /ID# 255262
    • Napoli
      • Naples, Napoli, Italië, 80131
        • Werving
        • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
    • Roma
      • Rome, Roma, Italië, 00165
        • Werving
        • Ospedale Pediatrico Bambino Gesu /ID# 255043
    • Aichi-ken
      • Ōbu, Aichi-ken, Japan, 474-8710
        • Werving
        • Aichi Children's Health And Medical Center /ID# 272085
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 277-0871
        • Werving
        • Tsujinaka Hospital - Kashiwanoha /ID# 268409
    • Fukuoka
      • Kurume-shi, Fukuoka, Japan, 830-0011
        • Werving
        • Kurume University Hospital /ID# 268418
    • Gunma
      • Maebashi, Gunma, Japan, 371-8511
        • Werving
        • Gunma University Hospital /ID# 270560
    • Kumamoto
      • Kumamoto, Kumamoto, Japan, 861-8520
        • Werving
        • Japanese Red Cross Kumamoto Hospital /ID# 268586
    • Osaka
      • Izumi-Shi, Osaka, Japan, 594-1101
        • Werving
        • Osaka Women's and Children's Hospital /ID# 268419
    • Saitama
      • Saitama-shi, Saitama, Japan, 330-8777
        • Werving
        • Saitama Children's Medical Center /ID# 268410
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan, 113-8519
        • Werving
        • Institute of Science Tokyo Hospital /ID# 269175
      • Fuchu-shi, Tokyo, Japan, 183-8561
        • Werving
        • Tokyo Metropolitan Children's Medical Center /ID# 268415
      • Setagaya City, Tokyo, Japan, 157-8535
        • Werving
        • National Center For Child Health And Development /ID# 268420
    • North Holland
      • Amsterdam, North Holland, Nederland, 1105 AZ
        • Werving
        • Amsterdam University Medical Center /ID# 254827
    • Kuyavian-Pomeranian Voivodeship
      • Torun, Kuyavian-Pomeranian Voivodeship, Polen, 87-100
        • Voltooid
        • Gastromed Sp. z o.o /ID# 255939
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 04-730
        • Werving
        • Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
      • Dorado, Puerto Rico, 00646
        • Werving
        • Puerto Rico Health Institute /ID# 255071
      • San Juan, Puerto Rico, 00909-1711
        • Werving
        • Clinical Research Puerto Rico /ID# 266479
      • Madrid, Spanje, 28009
        • Voltooid
        • Hospital Infantil Universitario Nino Jesus /ID# 255012
      • Málaga, Spanje, 29011
        • Werving
        • Hospital Regional Universitario de Malaga /ID# 257553
    • A Coruna
      • Ferrol, A Coruna, Spanje, 15405
        • Werving
        • Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
      • Changhua City, Changhua County, Taiwan, 50006
        • Werving
        • Changhua Christian Hospital /ID# 256082
      • Taipei, Taiwan, 100
        • Werving
        • National Taiwan University Hospital /ID# 255679
    • Praha 17
      • Prague, Praha 17, Tsjechië, 128 00
        • Voltooid
        • Vseobecna Fakultni nemocnice v Praze /ID# 256096
    • Praha 5
      • Prague, Praha 5, Tsjechië, 150 06
        • Voltooid
        • Fakultni nemocnice Motol a Homolka /ID# 256547
      • Ankara, Turkije (Türkiye), 06560
        • Werving
        • Gazi University Medical Faculty /ID# 255086
      • Istanbul, Turkije (Türkiye), 34453
        • Werving
        • Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
      • Istanbul, Turkije (Türkiye), 34899
        • Werving
        • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
      • Kocaeli, Turkije (Türkiye), 41380
        • Werving
        • Kocaeli University Med Faculty /ID# 256922
      • Birmingham, Verenigd Koninkrijk, B4 6NH
        • Werving
        • Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
    • England
      • Sheffield, England, Verenigd Koninkrijk, S10 2TH
        • Werving
        • Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
        • Contact:
          • Site Coordinator
          • Telefoonnummer: +44 114 273 0522
    • Greater London
      • London, Greater London, Verenigd Koninkrijk, E1 2ES
        • Werving
        • Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85016-7710
        • Werving
        • Phoenix Children's Hospital /ID# 255766
    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 72202
        • Voltooid
        • Arkansas Children's Hospital /ID# 255762
    • California
      • Oakland, California, Verenigde Staten, 94609
        • Werving
        • UCSF Benioff Children's Hospital - Oakland /ID# 258327
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • Children's Hospital Colorado - Aurora /ID# 255764
    • Florida
      • Orlando, Florida, Verenigde Staten, 32806-1141
        • Werving
        • Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Werving
        • Indiana University Health Riley Hospital for Children /ID# 256454
    • Massachusetts
      • Waltham, Massachusetts, Verenigde Staten, 02451
        • Werving
        • Massachusetts General Hospital - Mass General Waltham /ID# 255767
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55413-2195
        • Werving
        • MNGI Digestive Health, P. A. /ID# 255366
    • New Jersey
      • Morristown, New Jersey, Verenigde Staten, 07960
        • Werving
        • Goryeb Childrens Hospital /ID# 256452
    • New York
      • New York, New York, Verenigde Staten, 10029
        • Werving
        • Icahn School of Medicine at Mount Sinai /ID# 254880
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44195
        • Werving
        • Cleveland Clinic - Cleveland /ID# 256453
        • Contact:
          • Site Coordinator
          • Telefoonnummer: 216-636-2007
      • Daegu, Zuid -Korea, 41404
        • Werving
        • Kyungpook National University Chilgok Hospital /ID# 255817
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, Zuid -Korea, 03080
        • Werving
        • Seoul National University Hospital /ID# 255318
      • Seoul, Seoul Teugbyeolsi, Zuid -Korea, 06351
        • Werving
        • Samsung Medical Center /ID# 255284
      • Seoul, Seoul Teugbyeolsi, Zuid -Korea, 03722
        • Werving
        • Yonsei University Health System - Severance Hospital /ID# 256976
    • Stockholm County
      • Stockholm, Stockholm County, Zweden, 118 83
        • Werving
        • Sodersjukhuset /ID# 255239
      • Stockholm, Stockholm County, Zweden, 171 76
        • Werving
        • Astrid Lindgrens Barnsjukhus /ID# 255240
    • Västra Götaland County
      • Gothenburg, Västra Götaland County, Zweden, 413 46
        • Werving
        • Sahlgrenska Universitetssjukhuset /ID# 255236
        • Contact:
          • Site Coordinator
          • Telefoonnummer: +46313435865
      • Bern, Zwitserland, 3010
        • Werving
        • Inselspital, Universitaetsspital Bern /ID# 255321
    • Canton of Zurich
      • Zurich, Canton of Zurich, Zwitserland, 8032
        • Werving
        • Kinderspital Zurich - Eleonorenstiftung /ID# 255337

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

2 jaar tot 17 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Pediatric individuals, 2 to < 18 years old
  • Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
  • Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
  • Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies

Exclusion Criteria:

  • History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class

  • Any of the following medical disorders:

    1. Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.

    2. A diagnosis of CD prior to 2 years of age.

    3. A diagnosis or suspected diagnosis of a primary immunodeficiency.

    4. Currently known complications of CD such as:

      • Active abscess (abdominal or perianal);
      • Symptomatic bowel strictures;
      • > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
      • Fulminant colitis;
      • Toxic megacolon;
      • Or any other manifestation that might require surgery while enrolled in the study.
    5. Ostomy or ileoanal pouch.

    6. Diagnosis of short gut or short bowel syndrome.

    7. Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: PK Cohort 1: SS3 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: PK Cohort 1: SS3 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: PK Cohort 2: SS1

Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: PK Cohort 2: SS3 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: PK Cohort 2: SS3 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: Expansion Cohort 3: SS3 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: Expansion Cohort 3: SS3 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: PK Cohort 1: SS1

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: PK Cohort 1: SS2 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: PK Cohort 1: SS2 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: PK Cohort 2: SS2 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: PK Cohort 2: SS2 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: Expansion Cohort 3: SS1

Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: Expansion Cohort 3: SS2 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI
Experimenteel: Expansion Cohort 3: SS2 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andere namen:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andere namen:
  • ABBV-066
  • SKYRIZI

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Tijdsspanne: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Tijdsspanne: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Tijdsspanne: Up to approximately Week 64

Cmax of risankizumab

Up to approximately Week 64
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Tijdsspanne: Up to approximately 64 weeks

Tmax of risankizumab

Up to approximately 64 weeks
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Tijdsspanne: Up to approximately 64 weeks

AUCtau of risankizumab

Up to approximately 64 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Tijdsspanne: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Tijdsspanne: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tijdsspanne: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tijdsspanne: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Tijdsspanne: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Tijdsspanne: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Tijdsspanne: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Tijdsspanne: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Tijdsspanne: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tijdsspanne: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tijdsspanne: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Tijdsspanne: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: ABBVIE INC., AbbVie

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

11 december 2023

Primaire voltooiing (Geschat)

1 april 2029

Studie voltooiing (Geschat)

1 april 2029

Studieregistratiedata

Eerst ingediend

10 augustus 2023

Eerst ingediend dat voldeed aan de QC-criteria

10 augustus 2023

Eerst geplaatst (Werkelijk)

16 augustus 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

15 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • M16-194
  • 2022-502050-14-00 (Andere identificatie: EU CT)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-tijdsbestek voor delen

For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

IPD-toegangscriteria voor delen

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren